Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells
Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of m...
Gespeichert in:
Veröffentlicht in: | Experimental cell research 1996-10, Vol.228 (1), p.76-83 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 83 |
---|---|
container_issue | 1 |
container_start_page | 76 |
container_title | Experimental cell research |
container_volume | 228 |
creator | Warburton, Michael J. Dundas, Sinclair R. Gusterson, Barry A. O'Hare, Michael J. |
description | Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity. |
doi_str_mv | 10.1006/excr.1996.0301 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_excr_1996_0301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482796903018</els_id><sourcerecordid>8892973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EKqWwZYfkH0iZOGliL1HFS2pFVbXr4NjjYkjiyk4r-vcktGLHahZ3ztXVIeQ2hnEMkN3jt_LjWIhsDAnEZ2QYg4CIpYydkyFAnEYpZ_kluQrhEwA4j7MBGXAumMiTIXlf4mZXyda6hjpD19592UYGjFaHLdJFJUNtG7fBhj6o1u5l6zxdeKd36hcpD3QpWzqXdS39gc4PDre2_cDKyopOsarCNbkwsgp4c7ojsn56XE1fotnb8-v0YRapJBFtJJF3g1CzNBNZnpScGzA6ZTpDk2d6AgaFMqYEwJIpI7RWmACwdIJZroRIRmR87FXeheDRFFtv-1FFDEVvquhNFb2pojfVAXdHYLsra9R_7yc1Xc6POXar9xZ9EZTFRqG2HlVbaGf_q_4BzK56Mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</creator><creatorcontrib>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</creatorcontrib><description>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1006/excr.1996.0301</identifier><identifier>PMID: 8892973</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Basement Membrane - drug effects ; Basement Membrane - metabolism ; Cell Line ; Cytokines - pharmacology ; Enzyme Induction - drug effects ; Epithelial Cells ; Epithelium - drug effects ; Epithelium - metabolism ; Female ; Fibroblast Growth Factor 2 - pharmacology ; Growth Substances - pharmacology ; Hormones - pharmacology ; Hydrocortisone - pharmacology ; Interleukin-1 - pharmacology ; Mammary Glands, Animal - cytology ; Mammary Glands, Animal - drug effects ; Mammary Glands, Animal - metabolism ; Plasminogen Activators - biosynthesis ; Rats ; Tetradecanoylphorbol Acetate - pharmacology ; Transforming Growth Factor beta - pharmacology ; Urokinase-Type Plasminogen Activator - biosynthesis</subject><ispartof>Experimental cell research, 1996-10, Vol.228 (1), p.76-83</ispartof><rights>1996 Academic Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/excr.1996.0301$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8892973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Warburton, Michael J.</creatorcontrib><creatorcontrib>Dundas, Sinclair R.</creatorcontrib><creatorcontrib>Gusterson, Barry A.</creatorcontrib><creatorcontrib>O'Hare, Michael J.</creatorcontrib><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</description><subject>Animals</subject><subject>Basement Membrane - drug effects</subject><subject>Basement Membrane - metabolism</subject><subject>Cell Line</subject><subject>Cytokines - pharmacology</subject><subject>Enzyme Induction - drug effects</subject><subject>Epithelial Cells</subject><subject>Epithelium - drug effects</subject><subject>Epithelium - metabolism</subject><subject>Female</subject><subject>Fibroblast Growth Factor 2 - pharmacology</subject><subject>Growth Substances - pharmacology</subject><subject>Hormones - pharmacology</subject><subject>Hydrocortisone - pharmacology</subject><subject>Interleukin-1 - pharmacology</subject><subject>Mammary Glands, Animal - cytology</subject><subject>Mammary Glands, Animal - drug effects</subject><subject>Mammary Glands, Animal - metabolism</subject><subject>Plasminogen Activators - biosynthesis</subject><subject>Rats</subject><subject>Tetradecanoylphorbol Acetate - pharmacology</subject><subject>Transforming Growth Factor beta - pharmacology</subject><subject>Urokinase-Type Plasminogen Activator - biosynthesis</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EKqWwZYfkH0iZOGliL1HFS2pFVbXr4NjjYkjiyk4r-vcktGLHahZ3ztXVIeQ2hnEMkN3jt_LjWIhsDAnEZ2QYg4CIpYydkyFAnEYpZ_kluQrhEwA4j7MBGXAumMiTIXlf4mZXyda6hjpD19592UYGjFaHLdJFJUNtG7fBhj6o1u5l6zxdeKd36hcpD3QpWzqXdS39gc4PDre2_cDKyopOsarCNbkwsgp4c7ojsn56XE1fotnb8-v0YRapJBFtJJF3g1CzNBNZnpScGzA6ZTpDk2d6AgaFMqYEwJIpI7RWmACwdIJZroRIRmR87FXeheDRFFtv-1FFDEVvquhNFb2pojfVAXdHYLsra9R_7yc1Xc6POXar9xZ9EZTFRqG2HlVbaGf_q_4BzK56Mw</recordid><startdate>19961010</startdate><enddate>19961010</enddate><creator>Warburton, Michael J.</creator><creator>Dundas, Sinclair R.</creator><creator>Gusterson, Barry A.</creator><creator>O'Hare, Michael J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19961010</creationdate><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><author>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Basement Membrane - drug effects</topic><topic>Basement Membrane - metabolism</topic><topic>Cell Line</topic><topic>Cytokines - pharmacology</topic><topic>Enzyme Induction - drug effects</topic><topic>Epithelial Cells</topic><topic>Epithelium - drug effects</topic><topic>Epithelium - metabolism</topic><topic>Female</topic><topic>Fibroblast Growth Factor 2 - pharmacology</topic><topic>Growth Substances - pharmacology</topic><topic>Hormones - pharmacology</topic><topic>Hydrocortisone - pharmacology</topic><topic>Interleukin-1 - pharmacology</topic><topic>Mammary Glands, Animal - cytology</topic><topic>Mammary Glands, Animal - drug effects</topic><topic>Mammary Glands, Animal - metabolism</topic><topic>Plasminogen Activators - biosynthesis</topic><topic>Rats</topic><topic>Tetradecanoylphorbol Acetate - pharmacology</topic><topic>Transforming Growth Factor beta - pharmacology</topic><topic>Urokinase-Type Plasminogen Activator - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warburton, Michael J.</creatorcontrib><creatorcontrib>Dundas, Sinclair R.</creatorcontrib><creatorcontrib>Gusterson, Barry A.</creatorcontrib><creatorcontrib>O'Hare, Michael J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warburton, Michael J.</au><au>Dundas, Sinclair R.</au><au>Gusterson, Barry A.</au><au>O'Hare, Michael J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>1996-10-10</date><risdate>1996</risdate><volume>228</volume><issue>1</issue><spage>76</spage><epage>83</epage><pages>76-83</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8892973</pmid><doi>10.1006/excr.1996.0301</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4827 |
ispartof | Experimental cell research, 1996-10, Vol.228 (1), p.76-83 |
issn | 0014-4827 1090-2422 |
language | eng |
recordid | cdi_crossref_primary_10_1006_excr_1996_0301 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Basement Membrane - drug effects Basement Membrane - metabolism Cell Line Cytokines - pharmacology Enzyme Induction - drug effects Epithelial Cells Epithelium - drug effects Epithelium - metabolism Female Fibroblast Growth Factor 2 - pharmacology Growth Substances - pharmacology Hormones - pharmacology Hydrocortisone - pharmacology Interleukin-1 - pharmacology Mammary Glands, Animal - cytology Mammary Glands, Animal - drug effects Mammary Glands, Animal - metabolism Plasminogen Activators - biosynthesis Rats Tetradecanoylphorbol Acetate - pharmacology Transforming Growth Factor beta - pharmacology Urokinase-Type Plasminogen Activator - biosynthesis |
title | Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T00%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulation%20of%20Urokinase-Type%20Plasminogen%20Activator%20Production%20by%20Rat%20Mammary%20Myoepithelial%20Cells&rft.jtitle=Experimental%20cell%20research&rft.au=Warburton,%20Michael%20J.&rft.date=1996-10-10&rft.volume=228&rft.issue=1&rft.spage=76&rft.epage=83&rft.pages=76-83&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1006/excr.1996.0301&rft_dat=%3Cpubmed_cross%3E8892973%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8892973&rft_els_id=S0014482796903018&rfr_iscdi=true |